LinkMed logo
sp
sp divider
The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.
COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology
MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.

With focus on destructive joint diseases

Operations: AnaMar develops drugs and biomarkers for diagnosing and monitoring/predicting degenerative joint diseases such as rheumatoid arthritis and os-teoarthritis. AnaMar has one drug candidate at clinical trials, three drug candidates in preclinical trials, two biomarkers in prototype development and two commercial biomarkers, COMP®- Elisa and Animal COMP-Elisa.

Sektor: Drug development and biotechnology

Therapeutic area: Chronic joint diseases

CEO: Owe Gårlin

Chairman: Staffan Encrantz

Venture manager: Ingemar Lagerlöf

Ownership stake: 22.2%

Address: AnaMar AB
Kungsportsavenyn 22
SE-411 36 Göteborg
Sweden

www.anamar.com

Back